Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | R2032K |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM R2032K lies within the FAT domain of the Atm protein (UniProt.org). R2032K results in aberrant splicing of ATM mRNA, leading to skipping of exon 43 (PMID: 9887333), and decreased Atm kinase activity in patient-derived cells (PMID: 36029002), and therefore, is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM R2032K |
Transcript | NM_000051.4 |
gDNA | chr11:g.108315911G>A |
cDNA | c.6095G>A |
Protein | p.R2032K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017017790.2 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_017017789 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542843 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542840 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_005271562 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542844.4 | chr11:g.108329070G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_017017791 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_017017790 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
NM_000051 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_005271561 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542844.3 | chr11:g.108329070G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_006718843 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.108315911G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
XM_011542844 | chr11:g.108329070G>A | c.6095G>A | p.R2032K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM R2032K | prostate cancer | sensitive | Olaparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM R2032K, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). | detail... 32343890 detail... |